Drugs / aleglitazar
Trials 22
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 18 trials | ||||||
| Phase 1 | NCT01711775 | Nov → Dec 2012 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01701739 | Oct 2012 → Jan 2013 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01679639 | Aug → Dec 2012 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01615354 | Jul 2012 → Jan 2013 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01398267 | Aug 2011 → Oct 2012 | type 2 diabetes mellitus | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01197911 | Sep 2010 → Aug 2011 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01188304 | Jul → Oct 2010 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01188317 | Jun 2010 → Sep 2011 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 26 trials · 2 met primary | ||||||
| Phase 2 | NCT01729403 | Dec 2012 → Sep 2013 | type 2 diabetes mellitus | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT01680978 | Oct 2012 → Sep 2013 | type 2 diabetes mellitus | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT01043029 | May 2010 → Jul 2012 | type 2 diabetes mellitus | Hoffmann-La Roche | Completed | Met primary |
| Phase 2 | NCT00461006 | Jun 2007 → Sep 2008 | type 2 diabetes mellitus | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT00461058 | May → Dec 2007 | type 2 diabetes mellitus | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT00388518 | Nov 2006 → Mar 2008 | type 2 diabetes mellitus | Hoffmann-La Roche | Completed | Met primary |
| Phase 38 trials · 2 met primary · 1 missed | ||||||
| Phase 3 | NCT01893242 | Dec 2013 → Jan 2019 | diabetic kidney disease | Hoffmann-La Roche | Withdrawn | No outcome recorded |
| Phase 3 | NCT01871428 | Jun → Nov 2013 | type 2 diabetes mellitus | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT01871415 | May → Aug 2013 | type 2 diabetes mellitus | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT01691989 | Dec 2012 → Sep 2013 | type 2 diabetes mellitus | Hoffmann-La Roche | Completed | Met primary |
| Phase 3 | NCT01715818 | Dec 2012 → Nov 2013 | diabetes mellitus, noninsulin-dependent, 2 | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT01691755 | Nov 2012 → Sep 2013 | type 2 diabetes mellitus | Hoffmann-La Roche | Completed | Met primary |
| Phase 3 | NCT01691846 | Oct 2012 → Sep 2013 | type 2 diabetes mellitus | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT01042769 | Feb 2010 → Nov 2013 | type 2 diabetes mellitus | Hoffmann-La Roche | Completed | Missed primary |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 24 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Aleglitazar | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01893242 ↗ |
| Known as | R-1439 | ChEMBL registry synonym — accepted as the source's own label CHEMBL519504 ↗ |
| Known as | RO0728804 | “A Single-center, Non-randomized, Open-label Study to Assess the Pharmacokinetics of Aleglitazar (RO0728804) After Administration of Single and Multiple Oral Doses of 150 µg...” NCT01711775 ↗ |
| Action | Activate | “Peroxisome proliferator-activated receptor gamma agonist” CHEMBL519504 ↗2“Peroxisome proliferator-activated receptor alpha agonist” CHEMBL519504 ↗ “the dual PPAR-alpha and PPAR-gamma agonist aleglitazar” PMID 19515415 ↗ Jun 2009 |
| Modality | Small molecule | — CHEMBL519504 ↗ |
| Route | Oral | “Administered po daily” NCT00388518 ↗ |
| Target | PPARA | “Peroxisome proliferator-activated receptor alpha agonist” CHEMBL519504 ↗ |
| Target | PPARG | “Peroxisome proliferator-activated receptor gamma agonist” CHEMBL519504 ↗ |